Folditam (Folic Acid, Vitamin D3)
Brand Names: Folditam
Methodology & AI Transparency ⓘ
Folditam (Folic Acid, Vitamin D3) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within the Vitamin D category, Folditam provides branded delivery of active pharmaceutical ingredient Folic Acid, Vitamin D3 (registered by PureTek Corporation; NDC 59088-185).
- 2 Real-world patient consensus: Registered under RxNorm 2569082 and SPL 2023-01-11, pairing Folditam packaging with active ingredient Folic Acid, Vitamin D3.
- 3 Typical cash cost range: Public pharmacy ledger: $10.16 low cash benchmark vs. $34.50 chain retail average ($0.0231/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Folditam (Folic Acid, Vitamin D3): nausea (9.2%), headache (7.4%), dizziness (6.3%).
Ask our AI Specialists anything about Folditam (Folic Acid, Vitamin D3)
Folditam (Folic Acid, Vitamin D3) Mechanism, CYP450 Pathways & DailyMed Monograph
Within the Vitamin D category, Folditam provides branded delivery of active pharmaceutical ingredient Folic Acid, Vitamin D3 (registered by PureTek Corporation; NDC 59088-185). Characterized by 1 mg/1 / 250 ug/1 Tablet; Longitudinal Folditam (Folic Acid, Vitamin D3) dosing interval tailored to tolerability under 2023-01-11 SPL documentation, Folditam targets Folditam™ is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels.
Through its Folic Acid, Vitamin D3 active moiety, Folditam exerts vitamin d activity with class-characteristic hepatorenal disposition. Registered under NDC 59088-185 (registered by PureTek Corporation; effective 2023-01-11), the 1 mg/1 / 250 ug/1 Tablet; Longitudinal Folditam (Folic Acid, Vitamin D3) dosing interval tailored to tolerability presentation ensures reproducible pharmacokinetic release profiles documented in federal RxNorm (2569082) and CMS NADAC ($0.0231/unit) ledgers.
Clinical clearance of Folditam (Folic Acid, Vitamin D3) (Vitamin D) relies on mixed metabolic conjugation and unchanged urinary excretion across folditam (folic acid, vitamin d3) regimens with a Terminal t½ estimated at 10–14 hrs depending on renal/hepatic reserve (Folditam (Folic Acid, Vitamin D3)) half-life; patients absorbing at F ≈ 54%–66% systemic availability after standard oral Folditam (Folic Acid, Vitamin D3) administration bioavailability typically observe target onset around time to peak concentration spans 1 to 3 hrs under folditam (folic acid, vitamin d3) maintenance.
FDA clinical labeling for Folditam (Folic Acid, Vitamin D3) restricts administration in severe drug-induced hypersensitivity to folic acid, vitamin d3 or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2023-01-11 for folditam (folic acid, vitamin d3) across 1 mg/1 / 250 ug/1 Tablet, Longitudinal Folditam (Folic Acid, Vitamin D3) dosing interval tailored to tolerability, with self-reported patient tracking dominated by nausea (9.2% of reports), headache (7.4% of reports), dizziness (6.3% of reports).
Divalent and trivalent cations bind Folditam (Folic Acid, Vitamin D3) intraluminally and blunt peak oral plasma concentrations.
Assess baseline hepatic panels and interacting prescriptions when starting Folditam (Folic Acid, Vitamin D3) (vitamin d).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Folic Acid, Vitamin D3 or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2023-01-11 for Folditam (Folic Acid, Vitamin D3)
Logged Side-Effect Incidence (21 Reports)
Folditam (Folic Acid, Vitamin D3) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Folditam (Folic Acid, Vitamin D3))
Human clinical trial evidence for Folditam (Folic Acid, Vitamin D3) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Folditam (Folic Acid, Vitamin D3) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0231/unit (~$0.69/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $10.16 / mo | View logs ↓ |
Folditam (Folic Acid, Vitamin D3) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Folditam (Folic Acid, Vitamin D3) RxNorm Concept ID | 2569082 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0231 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $10.16 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 90.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Folditam (Folic Acid, Vitamin D3) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Folditam (Folic Acid, Vitamin D3) integrating DailyMed SPL (2023-01-11), CMS NADAC ($0.0231/unit), and 21 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Folditam (Folic Acid, Vitamin D3) community threads and patient logs by age, biological sex, dosage, and treatment duration.